$DXCM

Coleman Jon sold $359K of DXCM

Coleman Jon (EVP, Chief Commercial Officer) sold 4,912 shares of DEXCOM INC (DXCM) at $73.00 ($0.36M total) on 2026-06-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Coleman Jon
Published Jun 5, 2026, 8:17 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 5, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$DXCM
Neutral
medium confidence
Mentioned
$DXCM
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DXCMNeutralLow
01

Why it matters

This is a disclosure of an executed sale (4,912 shares at $73.00) with no stated reason beyond the pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor for patterns of insider activity, but this specific filing is unlikely to be a standalone catalyst.

03

What to watch

10b5-1 plans are often routine and can be scheduled regardless of outlook; the sale size relative to holdings may matter more than the headline.

Relevance 6/10Novelty 6/10Timing: Filed June 5; sale executed June 3 under 10b5-1

Background

The article is an SEC Form 4 insider transaction disclosure (officer/direct sale) for DexCom.

Company-level read

Ticker impact

$DXCMNeutralMedium confidence
Context

DexCom officer Coleman Jon sold 4,912 shares in an open-market transaction under a pre-arranged 10b5-1 plan, disclosed via Form 4.

Expected impact

Likely limited near-term price impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing provides a specific sale datapoint (size and price) but no accompanying company-specific operational or financial catalyst.

Market effects

Minimal—single-company insider transaction with no stated sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

If the market treats insider selling as a risk signal despite 10b5-1, DXCM could see short-lived negative sentiment even without fundamentals changing.

Key entities

  • DexCom, Inc.

    Company whose officer sale is disclosed on SEC Form 4.

  • Coleman Jon

    EVP, Chief Commercial Officer; sold shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DXCMHighAI 8/10

DexCom stock hits 52-week high at 91.99 USD

DexCom Inc (DXCM) stock reached a 52-week high of $92.01, with a 36% year-to-date return. The company reported Q2 revenue of $1.308B, up 13% YoY, and raised its financial guidance. Analysts increased price targets, with Piper Sandler setting a $95 target. DexCom's inclusion in the FDA's TEMPO program and a perfect Piotroski Score of 9 indicate strong financial health.

$DXCMMed

Is Wall Street Bullish or Bearish on DexCom Stock?

DexCom (DXCM) designs continuous glucose monitoring systems. The stock lagged the S&P 500 and XLV over 52 weeks but gained 37.2% YTD. After Q2 2026 results on Jul. 30, adjusted EPS was $0.70 and revenue $1.31B, up 13% YoY, beating estimates. DexCom raised 2026 revenue guidance to $5.18B-$5.25B. Canaccord lifted its price target to $90; mean target $92.48.